enGenes brings enhanced protein yield opportunities to EFIB Brussels


enGenes brings enhanced protein yield opportunities to EFIB Brussels


engenes_Logo_final1

Press Release | enGenes Biotech GmbH

SEPTEMBER 16, 2019

Vienna, Austria: – Recombinant protein specialist enGenes Biotech GmbH (enGenes) will be a new presence at the upcoming European Forum for Industrial Biotechnology & the Bioeconomy (EFIB 2019) in Brussels.

enGenes will use its first appearance at the annual partnering event to present successful applications of its proprietary enGenes-X-press technology in boosting recombinant protein and DNA yields to the Industrial Biotech sector.

Industrial biotech contribution

“This is an excellent opportunity to share latest news on our exciting enGenes-X-press platform. It has shown big potential to increase yields of recombinant proteins, even of difficult to express ones. We will reach out to new clients, establish new business relationships and share knowledge with leading figures in the industrial biotech arena,” commented enGenes CEO and CSO, Dr. Juergen Mairhofer.

E.coli-based platform

The enGenes team will make full use of the EFIB networked partnering platform to set up a series of one-to-one meetings in Brussels with potential clients and stakeholders in the Industrial Biotech sector.

“We will have a particularly compelling offer for companies having a need for cost-effective production using our E. coli protein expression platform,” said Dr. Mairhofer.

Protein production partner

“We will be able to show them that we can provide a reliable partnership for development of cost-effective manufacturing processes using enGenes-X-press technology, helping clients and partners save money by developing cost-effective manufacturing processes for enzymes or other recombinant proteins” he noted.

“We are also relevant partners for research project, as we have shown with various successful participation in EU or nationally funded projects such as XPAND, synBIOCarb and currently Rafts4Biotech,” Dr. Mairhofer concluded.

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-X-press™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes-X-press has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored around the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

About EFIB 2019

The annual European Forum for Industrial Biotechnology & the Bioeconomy (EFIB) has become one of Europe’s leading event for the bio-based economy.

The partnering forum brings together more than 500 delegates from some 30 countries and 280 business, policy and science organisations to discuss emerging trends in industrial biotechnology.

EFIB 2019 is a three-day event opening September 30 at The Square meeting center in Brussels.

More than 80 speakers will discuss current issues in various focused tracks, with numerous company and start-ups presenting innovations. A co-located exhibition showcases global brands, emerging innovators and academic poster presentations.

Organizer is Europa Bio with further information at: https://efibforum.com.

Media Contact

Dr. Juergen Mairhofer, CEO, enGenes Biotech
Tel: +43 1 93 46 707-0
Email: juergen.mairhofer@engenes.cc

Resources

Click on enGenes at EFIB 2019 Brussels for other information.
Click on enGenes Biotech GmbH to contact the company directly.
Click on Rafts 4 Biotech for more on enGenes participation in EU-funded project.


Supplier Information
Supplier: enGenes Biotech GmbH
Address: Mooslackengasse 17, 1190 Vienna, Austria
Tel: +43 1 93 46 707-0
Website: http://www.engenes.cc


Comments are closed.